Staphylococcus lugdunensis Urinary Tract Infection With Associated Neutropenic Fever

Rajanish Bobde 1, Joseph I. Berger 2, Urma Jalil 3, Garine Kalaydjian 2

1. Infectious Disease, St. John’s Riverside Hospital, Yonkers, USA 2. Internal Medicine, St. John’s Riverside Hospital, Yonkers, USA 3. Internal Medicine, Lake Erie College of Osteopathic Medicine, Greensburg, USA

Abstract

We present a 62-year-old woman with a history of uterine cancer status post-total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO) on paclitaxel, who presented to the emergency department febrile at 101.7 Fahrenheit and complaining of fatigue and urinary incontinence. Laboratory testing revealed neutropenia and urinalysis showed elevated bacteria with minimal white blood cells, and negative leukocyte and negative nitrates. Urine cultures ultimately showed Staphylococcus lugdunensis with negative blood cultures.

S. lugdunensis is a less frequently speciated Staphylococcus and has been increasingly found due to advances in identification using matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS). S. lugdunensis are Gram-positive cocci, nonsporulating, nonmotile, facultatively anaerobic, catalase-positive, coagulase-negative, oxidase-negative, delta-hemolytic organism. Traditionally, it is seen in skin and soft-tissue infections, as well as vascular infections, however, has minimal occurrences in urinary tract infections.

The risk of infection is increased in immunocompromised states and empiric treatment is warranted while waiting for definitive results. Our patient was started on cefepime, valacyclovir, fluconazole, and a single dose of vancomycin while in the emergency department. Worsening thrombocytopenia during her antibiotic course necessitated the re-evaluation of antibiotic agents which can cause thrombocytopenia. Subsequently, due to the patient’s improved clinical status, and low risk of severe outcome, fluconazole and valacyclovir were discontinued, and cefepime was changed to ceftriaxone.

Introduction

Staphylococcus lugdunensis was discovered in France in 1988 and has been increasingly isolated over the past decades [1]. Based on 11 clinical strains, S. lugdunensis have been categorized as Gram-positive cocci, nonsporulating, nonmotile, facultatively anaerobic, catalase-positive, coagulase-negative, oxidase-negative, delta-hemolytic, and susceptible to novobiocin [1]. Since that time, S. lugdunensis have been found over the entire surface of the human skin, but more commonly in the inguinal folds and lower half of the body [2-3]. Studies showed that the most common clinical diagnoses were skin and soft-tissue infections (55.4%) and vascular-associated infections (17.4%) [4]. There are very few occurrences of this bacteria causing urinary tract infections (UTIs). [5] One large-scale study demonstrated that only 6% of urine specimens (31 of a total of 4,652) found S. lugdunensis, with the greatest prevalence in women aged 65 or older [6]. Typically, infections were thought to sprout from trauma or immunosuppression, however, they have been found in healthy individuals as well [5]. Notably, there has been an increased incidence of infections with S. lugdunensis since 2014, likely due to the introduction of the matrix-assisted laser desorption ionization time-of-flight mass spectrometry which has offered a revolutionary technique for the identification of bacteria [7].

Case Presentation

Our patient is a 62-year-old female with a past medical history of uterine cancer status post-total abdominal hysterectomy–bilateral salpingo-oophorectomy (TAH-BSO), currently on paclitaxel (last therapy 10 days prior to admission), who presented to the hospital complaining of fatigue, fever, and urinary incontinence. Subsequent laboratory testing showed her to be neutropenic. Temperature max (Tmax) recorded at home was 101.7 degrees Fahrenheit, after which the patient took acetaminophen and presented to the hospital. Vitals, labs, urinalysis, urine culture, and blood cultures were ordered. Urinalysis showed elevated bacteria and minimal amounts of WBCs with no leukocyte esterase and no nitrates (Table 1). Cefepime, valacyclovir, fluconazole, and a single dose of vancomycin were started empirically in the emergency room. Following her 2nd day, Tmax peaked, and subsequently down-trended until she became afebrile on day 3. Filgrastim was administered on the 3rd hospital day and resulted in a transient increase in
WBCs, with no effect on platelet count which had continued to decrease. Her urine culture on day 5 reported *S. lugdunensis* sensitive to ceftriaxone as well as minimal amounts of *Enterococcus faecalis*. Blood cultures returned negative. Due to our patient’s low risk for complication as determined by her Multinational Association for Supportive Care in Cancer (MASCC) score of 24, and Clinical Index of Stable Febrile Neutropenia (CISNE) score of 1, cefepime, valaciclovir, and fluconazole were discontinued due to their potential to decrease platelets, and ceftriaxone was started instead and continued for 4 more days [8-10]. WBCs dropped again between days 5 through 7, and platelets decreased between days 7 and 8. A second dose of filgrastim was administered on day 7 resulting in an up-trending WBC on day 8 and an up-trending platelet count on day 9. WBCs declined on day 9, however, the absolute neutrophil count (ANC) remained in the normal range. Following this, the patient continued to recover and was discharged off antibiotics.

| Vitals & Laboratory Values |
|-----------------------------|
| **Home Vitals**             |
| **Temperature (°F)**        | 101.7 |
| **Vitals:**                 |     |
| **Temperature (°F)**        | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | Day 8 | Day 9 |
|                             | 99.6  | 101.9 | 98.9  | 98.4  | 98.2  | 98.6  | 98.2  | 98.5  | 98.2  |
| **Pulse (bpm)**             | 128   | 107   | 82    | 80    | 91    | 87    | 86    | 89    | 67    |
| **Blood Pressure (mmHg)**   | 128/64| 111/50| 100/60| 114/56| 125/70| 121/57| 106/55| 110/67| 109/66|
| **Oxygen Saturation (SpO₂ on room air)** | 97% | 97% | 96% | 96% | 97% | 95% | 97% | 98% | 99% |
| **Laboratory Values:**      |     |
| **White Blood Cells (K/mm³)** | 0.4 | 0.7 | 0.9 | 2.0 | 2.7 | 1.9 | 1.6 | 4.9 | 3.5 |
| **Absolute Neutrophil Count (K/mm³)** | 0.0 | 0.0 | 0.1 | 1.1 | 1.5 | 0.8 | 0.7 | 3.9 | 2.3 |
| **Hemoglobin (gm/dL)**      | 8.0   | 8.2   | 7.8   | 7.3   | 7.3   | 7.2   | 7.2   | 7.9   | 7.6   |
| **Hematocrit (% L/L)**      | 23.6  | 24.0  | 22.6  | 21.6  | 21.3  | 21.3  | 21.2  | 23.3  | 22.7  |
| **Platelets (K/µL)**        | 61,000| 51,000| 40,000| 36,000| 30,000| 30,000| 27,000| 25,000| 28,000|
| **Urinalysis:**             |     |
| **White Blood Cells (WBC/µL)** | 20  |
| **Red Blood Cells (RBC/µL)** | 49  |
| **Bacteria (Bact/µL)**      | 2,189|
| **Leukocyte Esterase**      | Negative |
| **Nitrites**                | Negative |
| **Urine Culture:**          |     |
| *Staphylococcus lugdunensis* > 100,000 colony-forming units |
| *Enterococcus faecalis* 20,000-30,000 colony-forming units |

**TABLE 1: Vitals and Laboratory Values**

| **Discussion** |

Febrile neutropenia is the occurrence of a fever in the setting of an ANC less than 1500. This increases the chance of infection, and possibly the severity of the infection [11]. Risk of disease course can be estimated by
the CISNE and MASCC scores and is considered to be low. It is standard therapy to be started on empiric antibacterial, antiviral, and antifungal treatment to prevent opportunistic infections [12]. Our patient suffered from persistent neutropenia as well as thrombocytopenia in the setting of recent chemotherapy. The increased susceptibility to infection, combined with profound thrombocytopenia required careful monitoring of both her antibiotic regimen and hemodynamic status.

Our patient developed a UTI with S. lugdunensis likely secondary to her neutropenia and the bacteria’s predilection for the inguinal area [2]. S. lugdunensis, in comparison to other coagulase-negative Staph species, has the potential for increased virulence due to its delta-like toxin resembling the delta-toxin in Staphylococcus aureus as well as increased resistance via acquiring the blaZ gene conferring penicillinase production. The delta-toxin of S. aureus increases virulence by forming membrane-damaging pores which result in cell lysis [7,13]. To date, the presence of meca gene, and thus methicillin resistance, among S. lugdunensis, is rare ranging from 0 to 8.3% [13]. Interestingly, compared to Staphylococcus saprophyticus, another coagulase-negative Staphylococcus (albeit with resistance to novobiocin) which also colonizes a similar area as S. lugdunensis, S. lugdunensis is more associated with patients who have solid organ tumors [7]. This raises the question of whether cancer-related immunosuppressive states permit S. lugdunensis infection whereas an S. saprophyticus infection might otherwise flourish. Additionally, unlike S. saprophyticus, which infrequently causes extra-genitourinary infection, S. lugdunensis has been implicated in skin and soft-tissue infections, respiratory infections, bacteremia, prostatic joint infections, and peritonitis [6].

It is important to note that despite the pan-sensitivity of our patient’s organism, we deemed it medically prudent to change antibiotics, and discontinue antifungal and antiviral therapy due to the patient’s persistent thrombocytopenia and overall low risk for viral and fungal pathogens. Reports have found correlations between antibacterial, antifungal, and antiviral medications causing thrombocytopenia, including cefepime, fluconazole, and valaciclovir [8-10].

While currently, most strains of S. lugdunensis are pan-sensitive to antibiotic therapy, due to its unique virulence and correlation with patients who have solid organ tumors as well as the potential for extra-genitourinary manifestation, we posit that greater surveillance for this bacteria is warranted, especially when it is isolated in cultures with colony-forming units greater than 100,000 [13].

Conclusions
S. lugdunensis is still relatively unrecognized as a urogenital pathogen and has not been found in sufficient quantity in many urine cultures as of date. Its presence in patients with solid organ tumors however must be considered. While it has been studied in the setting of skin and soft-tissue infections, further studies are required on its frequency of causing UTIs, as well as the potential for increasing virulence and resistance due to its unique genes.

Additional Information
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Freney J, Brun Y, Bes M, et al.: Staphylococcus lugdunensis sp. nov. and Staphylococcus schleiferi sp. nov., two species from human clinical specimens. Int J Syst Evol Microbiol. 1988, 38:168-72. 10.1099/00207713-38-2-168
2. van der Mee-Manquet N, Achard A, Mereghetti L, Danton A, Minier M, Quentin R: Staphylococcus lugdunensis infections: high frequency of inguinal area carriage. J Clin Microbiol. 2005, 43:1404-9. 10.1128/JCM.43.4.1404-1409.2005
3. Bieber L, Kahlmeter G: Staphylococcus lugdunensis in several niches of the normal skin flora. Clin Microbiol Infect. 2010, 16:385-8. 10.1111/j.1469-0691.2009.02813.x
4. Herchline TE, Ayers LW: Occurrence of Staphylococcus lugdunensis in consecutive clinical cultures and relationship of isolation to infection. J Clin Microbiol. 1991, 29:419-21. 10.1128/cm.29.3.419-421.1991
5. Frank KL, del Pozo JL, Patel R: From clinical microbiology to infection pathogenesis: how daring to be different works for Staphylococcus lugdunensis. Clin Microbiol Rev. 2008, 21:111-33. 10.1128/CMR.00036-07
6. Haile DT, Hughes I, Vetter E, Kohner P, Snyder R, Patel R, Cockerill FR: Frequency of isolation of Staphylococcus lugdunensis in consecutive urine cultures and relationship to urinary tract infection. J Clin Microbiol. 2002, 40:654-6. 10.1128/JCM.40.2.654-656.2002
7. Chiu KHY, Lam RPK, Chan E, Lau SKP, Woo PCY: Emergence of Staphylococcus lugdunensis as a cause of
urinary tract infection: results of the routine use of MALDI-TOF MS. Microorganisms. 2020, 8:381. 10.3390/microorganisms8030381
8. Lim PP, Chong CP, Aziz NA: Cefepime-associated thrombocytopenia in a critically ill patient. Int J Clin Pharm. 2011, 33:902-4. 10.1007/s11096-011-9571-5
9. Pasikhova Y, Ludlow SP: Fluconazole associated agranulocytosis and thrombocytopenia. Int J Clin Pharm. 2014, 36:268-70. 10.1007/s11096-014-9914-0
10. Katsenos S, Gkolas D, Nikolopoulou M: Acyclovir-induced immune thrombocytopenia in a patient with herpes zoster of the trigeminal nerve. Pharmacotherapy. 2010, 30:1085. 10.1592/phco.30.10.1085
11. Patel K, West H: Febrile neutropenia. JAMA Oncol. 2017, 3:1751. 10.1001/jamaoncol.2017.1114
12. Freifeld AG, Bow EI, Sepkowitz KA, et al.: Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011, 52:e56-93. 10.1093/cid/cir073
13. Taha L, Stegger M, Söderquist B: Staphylococcus lugdunensis: antimicrobial susceptibility and optimal treatment options. Eur J Clin Microbiol Infect Dis. 2019, 38:1449-55. 10.1007/s10096-019-03571-6